Lacouture, Mario E.
Goldfarb, Shari B.
Markova, Alina
Chawla, Sant P.
Dewnani, Karan
Iacobucci, Marc http://orcid.org/0000-0001-9959-3763
Lang, Julie E.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer
https://doi.org/10.1007/s10549-022-06584-6
Article History
Received: 8 November 2021
Accepted: 27 March 2022
First Online: 26 April 2022
Declarations
:
: The following authors report holding a consultant/advisory role, having stock ownership, or receiving research funding from NanOlogy; M.E.L., S.B.G., A.M., S.P.C., K.D., M.I., and J.E.L.
: Investigational Review Boards for all participating clinical sites provided approval for protocol and informed consents for subjects in accordance with the Code of Federal Regulations and local requirements.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients included in the study.